

EXMceuticals

11:26 10 Sep 2019

EXMceuticals enjoying 'exciting' time as it advances in Portugal, Uganda, and Malawi

EXMceuticals Inc (CSE:EXM) has outlined an 'exciting period' for the small cannabis company in its latest corporate update, published on Tuesday, which highlighted activity in Uganda, Portugal and Malawi and revealed that it has struck two loan agreements.

The company's farming operations are in central Africa and it wants to grow into one of the biggest wholesale grower, producer and supplier of cannabis and cannabidiol (CBD) ingredients to the pharmaceutical, nutraceutical, therapeutical and cosmetic markets in Europe and North America.

READ: EXMceuticals is a small cannabis company with big dreams to produce CBD on an industrial scale

The firm has a newly constructed research and development (R&D) facility in Lisbon, Portugal for the study of CBD and terpene formulations. The company said it is expecting to receive an initial license in September there which would allow it to import, research and refine cannabinoids within Europe.

EXMceuticals also revealed it was on the "verge" of signing a partnership with a leading UK university, in addition to the partnership it already has in place with Nova University, Lisbon.

In additions, the company is finalizing its joint venture with GFR Pharmaceutical - Canada's biggest white-label nutraceutical company - which will establish and operate a production facility to distribute full spectrum hemp oil products across North America.

In Malawi, the firm said it will soon sign formal agreements for the acquisition of a prize farming and processing asset in the country.

The 2,000-hectare farm and the factory is fully staffed and operational, already generates revenues, and is actively growing and distributing mangos to Europe and India. It is hoped that a cannabis cultivation and export license will be received before the middle of October.

In Uganda, the company has built and installed a fully operational extraction plant which has been tested with harvested cannabis. EXMceuticals is further developing its nursery operations and farming infrastructure on the 2,000 hectare asset.

Financing boost

The Vancouver- headquartered group also announced that it has struck two agreements with its president Jonathan Summers, who will provide the company with a loan of C\$600,000 and a loan facility of up to C\$1.4 million.

The loans, which are unsecured, are repayable in December 2019 and January 2021 and bear interest at 10% and 12% a year, respectively.

Price: 0.17

Market Cap: \$12.78 m

1 Year Share Price Graph



February 2020 August 2020 February 2021

Share Information

Code: EXM

Listing: CSE

52 week High Low
0.55 0.05

Sector: Cannabis

Website: exmceuticals.com

Company Synopsis:

EXMceuticals is a medical cannabis company that strongly believes in the potential health and wellness benefits of hemp and cannabis. EXMceuticals is an emerging player in the market, with high ambitions and potential in becoming a large scale producer of high-grade EU GMP cannabis and hemp ingredients.

action@proactiveinvestors.com

The company said it has issued bonus special warrants to Summers, which entitle him to acquire bonus shares in the company at a price of C\$1.35 per share for 20% of the principal amount actually funded under the loans.

Shares added 1.45% in Toronto to stand at C\$1.40 each on Tuesday.

Contact the author at giles@proactiveinvestors.com

Follow him on Twitter @Gile74

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of EXMceuticals named herein, including the promotion by the Company of EXMceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).